Abstract: The present invention provides a vaccine product comprising a container, wherein the container comprises an internal surface, the internal surface comprising either (i) silicon dioxide, (ii) a polymeric material, or (iii) a surface treated with ethylene oxide; and a vaccine composition within the container in contact with the internal surface, wherein the vaccine composition comprises virus particles.

Abstract: A cooling element includes a container, the container defining an internal volume within one or more walls of the container. The volume is air-tight sealed, and the container is configured for containing dry ice (solid carbon dioxide), releasing carbon dioxide gas from the volume and blocking ingress of ambient gas into the volume. Additionally, a shipping box includes a thermally insulated volume therein, and is configured for holding a receptacle and one or more cooling elements, wherein the one or more cooling elements are arranged to enclose the receptacle. Further, a method is disclosed for thermal stabilisation of such a receptacle by using the cooling element or shipping box. The receptacle is arranged for holding a product such as a (bio)pharmaceutical substance and/or advanced therapy medicinal product(s).

Abstract: Described are compositions comprising enveloped viruses that are not MVA, a sulfate salt at a concentration of about 5 mM to about 300 mM and a buffer, and the composition has a pH of about 6.0 to about 8.5. It also discloses methods for stabilizing an enveloped virus composition by preparing said viral formulation.

Abstract: Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.

Abstract: Described herein are compositions and pharmaceutical compositions including poxviruses, in particular vaccinia virus such as modified vaccinia Ankara (MVA) virus, a sulfate salt at a concentration between about 5 mM and 300 mM and a buffer, wherein the composition has a pH of between about 6.0 and 8.5. Also described are methods for stabilizing a poxvirus composition by preparing said viral formulation.

Abstract: Described are compositions comprising enveloped viruses that are not MVA, a sulfate salt at a concentration of about 5 mM to about 300 mM and a buffer, and the composition has a pH of about 6.0 to about 8.5. It also discloses methods for stabilizing an enveloped virus composition by preparing said viral formulation.

Abstract: The present invention is directed to stable protein formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing therapeutic proteins in aqueous solution.